Gene activation technology regulatory update

TKTX received U.S. Patent No. 5,968,502 covering ex vivo gene therapy using cells modified by TKTX's gene activation technology. The company said its technology covers multiple proteins including erythropoietin (EPO), Factor VIII, Factor IX, insulin, glucocerebrosidase and growth hormone. ...